News | May 28, 2026
Morepen Labs posts strong Q4 FY26 net profit
For the full year, standalone gross revenue crossed Rs. 1,700 crore
For the full year, standalone gross revenue crossed Rs. 1,700 crore
This multi-year CDMO agreement involves significant, ongoing manufacturing for a global pharmaceutical major
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
Scores highest PAT of Rs. 118 crore in FY25
The company is targeting a Rs. 1,000 crore finished dosages business within the next five years
Morepen Labs successfully raised Rs. 200 Crore through QIP
Fexofinadine is the most widely used, second-generation antihistamine drug for the treatment of allergy symptoms and hay fever
The new devices company will scale up its teams to create a world-class R&D centre for medical devices in India
The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.
The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
